Bitter melon (Momordica charantia L.) has traditionally been used as a medicinal food in many developing countries. It is a tropical fruit claimed to have therapeutic effects due to its content of bioactive compounds. The present review is an attempt to highlight the bitter melon varieties, bioactive composition that is linked to its therapeutic effects, especially antidiabetic effect, in vitro and in vivo models, and understanding of the mechanisms of actions of bitter melon that are associated with epidemiological evidences. This paper also outlines a proposed processing scheme aiming to fully utilize bitter melon and add further value to this fruit.

Bitter melon (Momordica charantia L.) is a tropical fruit claimed to have medicinal properties associated with its content of phenolic compounds (TPC). The aim of the study was to compare water with several organic solvents (acetone, butanol, methanol and 80% ethanol) for its efficiency at extracting the TPC from freeze-dried bitter melon powder. The TPC of the extracts was measured using the Folin-Ciocalteu reagent and their antioxidant capacity (AC) was evaluated using three assays. Before optimisation, the TPC and AC of the aqueous extract were 63% and 20% lower, respectively, than for the best organic solvent, 80% ethanol. However, after optimising for temperature (80 °C), time (5 min), water-to-powder ratio (40:1 mL/g), particle size (1 mm) and the number of extractions of the same sample (1×), the TPC and the AC of the aqueous extract were equal or higher than for 80% ethanol. Furthermore, less solvent (40 mL water/g) and less time (5 min) were needed than was used for the 80% ethanol extract (100 mL/g for 1 h). Therefore, this study provides evidence to recommend the use of water as the solvent of choice for the extraction of the phenolic compounds and their associated antioxidant activities from bitter melon.

Our aim was to optimise the encapsulation of an aqueous bitter melon extract by spray-drying with maltodextrin (MD) and gum Arabic (GA). The response surface methodology models accurately predicted the process yield and retentions of bioactive concentrations and activity (R² > 0.87). The optimal formulation was predicted and validated as 35% (w/w) stock solution (MD:GA, 1:1) and a ratio of 1.5:1 g/g of the extract to the stock solution. The spray-dried powder had a high process yield (66.2% ± 9.4%) and high retention (>79.5% ± 8.4%) and the quality of the powder was high. Therefore, the bitter melon extract was well encapsulated into a powder using MD/GA and spray-drying.